Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
Contemp Clin Trials Commun
; 15: 100385, 2019 Sep.
Article
em En
| MEDLINE
| ID: mdl-31338476
AD, Alzheimer's disease; Agitation; Alzheimer's disease; CB, cannabinoids; CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; CGIC, Clinician's Global Impression of Change; CMAI, Cohen Mansfield Agitation Inventory; Cannabinoid; Clinical trial; EC50, half maximal effective concentration; FDA, Food and Drug Administration; IPA, International Psychogeriatric Association; LTC, long-term care; MAR, Medication Administration Record; MNA-SF, Mini-Nutritional Assessment-Short form; NPI-NH, Neuropsychiatric Inventory-Nursing home version; NPS, neuropsychiatric symptoms; Neuropsychiatric symptoms; PAINAD, Pain Assessment in Advanced AD; RCT, randomized controlled trial; SIB, Severe Impairment Battery; THC, tetrahydrocannabinol; sMMSE, standardized Mini-Mental Status Examination
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Guideline
Aspecto:
Patient_preference
Idioma:
En
Revista:
Contemp Clin Trials Commun
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Canadá